Clinical Trial Update: Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study [Phase 2]

View source ↗

Summary

Phase 2 trial update of Ledipasvir/Sofosbuvir fixed-dose combination with or without ribavirin in chronic genotype 1 HCV patients who had prior Gilead-sponsored…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Gilead Sciences | Conditions: HCV Infection | Phase 2 | Status: COMPLETED | Results posted: 2017-01-10